Actinium's ATNM-400 Shows Preclinical Activity in Therapy-Resistant Breast Cancer Models
Bitget2026/11/02 13:03- Actinium Pharmaceuticals will present preclinical ATNM-400 breast cancer findings at the San Antonio Breast Cancer Symposium on December 9, 2026.
- The investigational HER3-targeted alpha therapy demonstrated efficacy across treatment-resistant breast cancer subtypes, building on previously reported activity in other solid tumor models.
- The findings support broader evaluation across solid tumors, complementing ATNM-400's ongoing first-in-human clinical development in prostate cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
